Volume 7.31 | Aug 11

Mesenchymal Cell News 7.31 August 11, 2015
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MESCN on Twitter
Altered Mesenchymal Niche Cells Impede Generation of Normal Hematopoietic Progenitor Cells in Leukemic Bone Marrow
Investigators demonstrated that the proliferative capability and differentiation potential of T cell lymphocytic leukemia (T-ALL) mesenchymal stem cells (MSCs) were impaired due to accelerated cellular senescence. Osteoprotegerin was identified as a cytokine to improve the function of T-ALL MSCs and to enhance normal hematopoietic progenitor cell output via the p38/ERK pathway. [Leukemia] Abstract
Animal Component-Free MSC Chondrogenic Differentiation
PUBLICATIONS (Ranked by impact factor of the journal)
FGF8 Signaling Sustains Progenitor Status and Multipotency of Cranial Neural Crest-Derived Mesenchymal Cells In Vivo and In Vitro
Scientists present evidence that FGF8 signaling is able to sustain progenitor status and multipotency of cranial neural crest (CNC)-derived mesenchymal cells both in vivo and in vitro. CNC-derived mesenchymal cells with Fgf8 overexpression or control cells in the presence of exogenous FGF8 exhibits prolonged survival, proliferation, and multi-potent differentiation capability in cell cultures. [J Mol Cell Biol] Abstract

Autocrine Action of Thrombospondin-2 Determines the Chondrogenic Differentiation Potential and Suppresses Hypertrophic Maturation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
Investigators demonstrated differentiation potential of human umbilical cord blood-derived MSCs (hUCB-MSCs) obtained from different individual donors varies, and they investigated the molecular basis for this variation. To assess the association between thrombospondin-2 (TSP2) and the differentiation potential, they evaluated chondrogenic differentiation of hUCB-MSCs treated with TSP2 siRNA. [Stem Cells] Abstract

Cell-Mediated Dexamethasone Release from Semi-IPNs Stimulates Osteogenic Differentiation of Encapsulated Mesenchymal Stem Cells
Researchers demonstrated that PEG-bis-(2-acryloyloxy propanoate)/dexamethasone-conjugated hyaluronic acid semi-IPNs can provide cell-mediated release of bioactive free dexamethasone that induces human mesenchymal stem cells osteogenic differentiation. This approach offers an efficient system for local delivery of osteogenic molecules empowering point of care applications. [Biomacromolecules] Abstract

Cartilage Repair Using Composites of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells and Hyaluronic Acid Hydrogel in a Minipig Model
The authors confirmed the consistent regenerative potential of cartilage regeneration potential of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in a pig model using three different cell lines. The cellular characteristics of the human umbilical cord blood-derived mesenchymal stem cells influenced the degree of cartilage regeneration potential. [Stem Cells Transl Med] Abstract | Full Article

Effects of Exendin-4 on Bone Marrow Mesenchymal Stem Cell Proliferation, Migration and Apoptosis In Vitro
Mesenchymal stem cells (MSCs) were isolated from bone marrow and cultured in vitro. After treatment with Ex-4, MSCs displayed a higher proliferative capacity, increased C-X-C motif receptor 4 (CXCR4) expression and an enhanced migration response. [Sci Rep] Full Article

Mesenchymal Stem Cells Regulate Melanoma Cancer Cells Extravasation to Bone and Liver at Their Perivascular Niche
Investigators report that local mesenchymal stem cells, acting as pericytes, regulate the extravasation of melanoma cancer cells specifically to murine bone marrow and liver. [Int J Cancer] Abstract

Growth Factors Cross-Linked to Collagen Microcarriers Promote Expansion and Chondrogenic Differentiation of Human Mesenchymal Stem Cells
Collagen microcarriers cross-linked with basic fibroblast growth factor (bFGF) or transforming growth factor-β1 (TGF-β1) were used for expansion and chondrogenic differentiation of human mesenchymal stem cells (MSC). Chondrogenic differentiation of MSC was induced by TGF-β1 cross-linked on microcarriers, promoting gene expression and protein accumulation of aggrecan, collagen type I and type II, as well as proteoglycans. [Tissue Eng Part A] Abstract

The Synergistic Effect of VEGF and Biomorphic Silicon Carbides Topography on In Vivo Angiogenesis and Human Bone Marrow Derived Mesenchymal Stem Cell Differentiation
Investigators established the influence of biomorphic silicon carbide ceramics surface topography on the proliferation and osteoblastic differentiation of mesenchymal stem cells and the potential synergistic effect of the ceramic porous structure together with vascular endothelial growth factor loading (VEGF) on the surface mediated osteoblastic differentiation. [Biomed Mater] Abstract

Bone Marrow-Derived Mesenchymal Stem Cells Co-Expressing Interleukin-18 and Interferon-β Exhibit Potent Antitumor Effect Against Intracranial Glioma in Rats
Researchers detected the effect of bone marrow-derived mesenchymal stem cells (BMSCs) co-expressing interleukin (IL)-18 and interferon (IFN)-β, both of which are immunostimulatory cytokines. BMSCs were genetically engineered to express IL-18 and IFN-β by transfection of recombinant lentivirus-mediated gene transfer. [Oncol Rep] Abstract

Learn more about our cell attachment substrates and matrices for stem cell research.
The Potential of Mesenchymal Stem Cells in the Management of Radiation Enteropathy
The authors discuss the advances in anticancer therapy by using mesenchymal stem cells after analyzing the pathogenesis of radiation enteropathy, introducing the advances in managing radiation enteropathy using regenerative therapy and exploring the putative actions by which mesenchymal stem cells repair intestinal injuries. [Cell Death Dis] Full Article

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Stem Cells & Regenerative Medicine Congress 2015
BrainStorm Cell Therapeutics Announces Completion of Enrollment in Phase II Clinical Trial of NurOwn® in ALS
BrainStorm Cell Therapeutics Inc. announced that it has completed enrollment in its ongoing randomized, double-blind placebo-controlled Phase II clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS). [BrainStorm Cell Therapeutics Inc.] Press Release

Cytovance® Biologics Inc. Announces Development & Manufacturing Deal With NeuroFx for Stem-Cell-Derived Cell-Free Therapy for Strokes
Cytovance® Biologics, Inc. announced that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions. [Cytovance® Biologics, Inc. (Marketwired)] Press Release

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW The 3rd International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
October 22-24, 2015
Berlin, Germany

Visit our events page to see a complete list of events in the mesenchymal cell community.
NEW Postdoctoral Biologist/Cytogeneticist Researcher – Genomic Stability of Cultured HSCs and MSCs (University of Crete)

Professorship – Cellular and/or Molecular Biology and Immunology (Nanjing University)

Cellular Therapy Faculty (University of California, San Diego)

Cell Biology Lab Manager (Harvard Apparatus Regenerative Technology)

Science Writer (Houston Methodist Research Institute)

Researcher – Stem Cell Research (Helse Bergen – Haukeland University Hospital)

Scientific Writer – Stem Cells and Regenerative Medicine (University of Washington)

Postdoctoral Fellow – Stem Cell Biology (INSERM)

Postdoctoral Position – Stem Cells (Technion – Israel Institute of Technology)

Postdoctoral Fellow/Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us